Physician profile
Nancy Pagan
NPI 1154334761
$1,529.58
in general payments reported to CMS, 2019-2025
23 companies · $80.14 in 2025
The $80.14 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.38 · 2022: $341 · 2023: $663 · 2024: $430 · 2025: $80.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $266.85 | 2022-2023 | Xarelto |
| Glaxosmithkline, LLC. | $266.44 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Scilex Pharmaceuticals INC. | $140.54 | 2022-2024 | Ztlido |
| Amgen INC. | $115.97 | 2022-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $103.63 | 2022-2025 | |
| Astellas Pharma US INC | $83.20 | 2023-2025 | Myrbetriq, Veozah |
| Lilly USA, LLC | $76.76 | 2023 | Mounjaro, Lyumjev, Baqsimi |
| Merck Sharp & Dohme LLC | $71.90 | 2023-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.37 | 2024 | Stiolto Respimat, Jardiance |
| Pfizer INC. | $42.81 | 2024 | |
| Esperion Therapeutics, INC. | $39.77 | 2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $32.20 | 2024 | Farxiga |
| Mannkind Corporation | $32.12 | 2022-2023 | Afrezza |
| Lundbeck LLC | $31.71 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $24.77 | 2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.25 | 2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $21.32 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $21.14 | 2023 | Trintellix |
| Cmp Pharma, INC. | $18.16 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.14 | 2023 | |
| Mylan Specialty L.P. | $16.09 | 2023 | Yupelri |
| Acadia Pharmaceuticals INC | $15.38 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.06 | 2023 | Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Pagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.